Ameritox's Ingenuity Health Announces Research Study from UCLA Center for Health Services and Society

BALTIMORE, Nov. 15, 2016 /PRNewswire/ -- Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of Ameritox^SM, today announced it has commissioned a research study by the UCLA Center for Health Services and Society that will help establish the first clinical guidelines for the use of urine drug monitoring among behavioral health patients who have been diagnosed with a serious mental illness. The research for the study has been completed, and the analysis is forthcoming.

"Using urine drug monitoring is still a very new concept in behavioral health, and this study will give us a solid understanding of how clinicians are utilizing it now, and how it's helping those same clinicians in treating their patients," said Ameritox Chief Medical Officer Thomas Smith, MD.

The UCLA Center for Health Services and Society was selected for their expertise in enhancing the health of communities; access to and quality of care; and qualitative research. All Center publications undergo a rigorous peer review process to verify the accuracy of findings and to gauge their relevance and utility to intended audiences.

The research findings will be announced by both Ameritox and the UCLA Center for Health Policy Research. Please visit http://hss.semel.ucla.edu for more information about this research institution.

About Ingenuity Health
As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.

Visit the Ingenuity Health website at: www.ingenuityhealth.com  
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox 
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com  
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact:
Genevieve Rozansky
30 Point Strategies
[email protected]
202-509-0794

Alexander Young, MD MSHS
UCLA Center for Health Services and Society
10920 Wilshire Blvd., Suite 300
Los Angeles, CA 90024
310-794-7219

SOURCE Ameritox